Latest Posts
-
Finance 0
Can Railroads Prosper Under The Trump Administration?
It is a fact that declining coal shipments have hurt railroad stocks in the past few years. Given that coal is a key revenue-generating commodity for railroad operators, headwinds related to the commodity had affected sector participants big time. However, things are looking up for this key sector. Let’s find out why. Trump Victory a Boon for Railroads? The victory of President Trump in Nov 2016 turned into a blessing for the sector. This is because of Trump’s pro-coal stance and emphasis on the need to revive the coal industry. He even went on to say, “Coal will last for 1,000 years in this country.” Coal is by far the most stable ... -
Finance 0
Not Yet Time To ‘Gamble’ On Ocwen Despite Sharp Decline, Says Oppenheimer
Oppenheimer analyst Ben Chittenden, in a note to investors entitled “If You Want to Gamble, Go to Foxwoods,” said it is “very hard” to fully know the outcome of the cease and desist orders and CFPB lawsuit against Ocwen but they, at the least, push out any potential turn in profitability. While he isn’t ready to call into question the company’s ability to survive, 20 states banding together to express serious concern regarding Ocwen as a going concern isn’t something he would just dismiss either, Chittenden stated. “There may come a time when it’s worth exploring a long position in OCN; we... -
Finance 0
Samsung Bioepis’ Knockoff Latest Competition For Johnson & Johnson’s Blockbuster, Remicade
Johnson & Johnson (JNJ)’s Remicade earned close to $7 billion last year, making it by far the biggest drug in their portfolio, but the FDA has approved a new knockoff…which may finally start to shift the market dynamics toward greater competition with lower prices. Written by John Carroll (ENDpts.com) The FDA approval was unusual among the recent bio-similar approvals as it came without an FDA expert panel review, signaling that the agency is becoming increasingly comfortable in rolling out new OKs for this class of drugs. The knockoff drug is dubbed Renflexis and comes from Samsung Bioepis, one of the big players in the bio-sim... -
Finance 0
TIPping Points?
The Federal Reserve’s complete change last year wasn’t something that happened all at once. There were several hints that a lot was going on behind the scenes that may never become public, including five years (now four) down the road when the full policy transcripts are released to the public. There was more interest in R* and secular stagnation, for one, as well as changing thoughts on inflation expectations. The latter has been an important topic for policymakers all along, but more so going back to early 2012. After all, by last March the PCE Deflator hadn’t registered 2% in compliance with the Fed’s mandate for four years at tha... -
Finance 0
Stocks Rally On Fiscal Policy Progress
The stock market rallied on Thursday as it appears the mini 3% correction is over. As I’ve mentioned, there is a large group of investors who are dying to get into the market. Whenever there is a 5% correction, they plow money into stocks. Because 5% corrections have become rare, these bullish investors preempt them by buying stocks earlier. This strategy sounds dumb on face value because it ignores the fundamentals, but it has been reinforced by a rising stock market. Even though it’s irrational, it has worked which means the fund managers using this strategy have multiplied. Being a good investor means ignoring rational arguments someti... -
Finance 0
French Presidential Election, Political Risk And Global Economic News
On this week’s episode of Market Week in Review, Investment Strategist Paul Eitelman joins Sophie Antal-Gilbert, program director, advisor insights, to discuss both the French presidential election and UK snap election, as well as the week’s global economic news.... -
Finance 0
Stifel Tells Investors To Buy SeaWorld, Six Flags
Research firm Stifel started coverage of several amusement park operators with Buy ratings, telling investors that SeaWorld (SEAS) should benefit from its strong management team, while Six Flags’ (SIX) valuation is attractive. SEAWORLD: Analyst Steven Wieczynski says that the stock has a better risk/reward ratio than any other theme park name he covers. The company’s new management team has “considerable regional theme park operations experience” and should be able to execute on its turnaround plan, the analyst believes. SeaWorld’s ability to expand overseas without investing a great deal of money is “under...
Top Posts
-
The Importance for Individuals to Use Sustainable Chemicals
-
Small Businesses: Finding the Right Candidate for the Job
-
How to Write the Perfect Thank You Letter After Your Job Interview
-
3 Best Large-Cap Blend Mutual Funds For Enticing Returns
-
China suspected in massive breach of federal personnel data
